<DOC>
	<DOCNO>NCT01103154</DOCNO>
	<brief_summary>Carvedilol show superior propranolol reduce portal pressure . This study undertaken compare effectiveness complication rate nadolol isosorbide mononitrate ( ISMN ) carvedilol prevention rebleeding esophageal varix .</brief_summary>
	<brief_title>A Trial Nadolol Plus Isosorbide Mononitrate Versus Carvedilol Prevention Variceal Rebleeding</brief_title>
	<detailed_description>Bleeding esophageal varix severe complication portal hypertension . After initial control acute variceal bleeding , patient 70 % risk rebleeding . Of rebleed , 20 % -35 % mortality rate . Therefore , preventive procedure require patient survive episode acute variceal bleeding . Both endoscopic injection sclerotherapy ( EIS ) propranolol well document effective prevention variceal rebleeding . In recent year , endoscopic variceal ligation ( EVL ) replace EIS endoscopic treatment choice management bleed esophageal varix . On hand , addition isosorbide-5-mononitrate ( ISMN ) show even effective propranolol alone reduction portal pressure prevention variceal rebleeding . A controlled trial show combination nadolol ISMN good EIS term prevention variceal rebleeding complication . The combination nadolol ISMN show well EVL prevent variceal rebleeding . However , study show contradictory result . On hand , carvedilol show superior propranolol reduce portal pressure . This study undertaken compare effectiveness complication rate nadolol ISMN carvedilol prevention rebleeding esophageal varix .</detailed_description>
	<mesh_term>Carvedilol</mesh_term>
	<mesh_term>Nadolol</mesh_term>
	<mesh_term>Isosorbide-5-mononitrate</mesh_term>
	<mesh_term>Isosorbide Dinitrate</mesh_term>
	<mesh_term>Isosorbide</mesh_term>
	<criteria>1. acute recent bleed esophageal varix ( define ) , 2. etiology portal hypertension cirrhosis , 3. age 20 70 year old . 1. association hepatocellular carcinoma malignancy , 2. association cerebral vascular accident , uremia , sepsis debilitate disease , 3. history gastric variceal bleeding , 4. receive betablocker within 1 month prior entry , 5. history contraindication use betablockers , asthma , heart failure , atrioventricular block , bradycardia ( pulse rate &lt; 55/min ) arterial hypotension ( systolic blood pressure &lt; 90 mmHg ) , 6. history prior shunt operation , TIPS ( transjugular intrahepatic portosystemic stent shunt ) , 7. deep jaundice ( serum bilirubin &gt; 10 mg/dl ) , 8. encephalopathy great stage II , 9. failure control index variceal bleeding , 10. refuse participate trial .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>beta blocker</keyword>
	<keyword>variceal rebleeding</keyword>
	<keyword>efficacy safety reduce variceal rebleeding</keyword>
</DOC>